Skip to Content

Posts tagged with "Drug Development"

  • Academia (vs. Industry)

    Stuart Schreiber on Stuart Schreiber

    The April issue of Drug Discovery Today has an intriguing interview (PDF file) with Stuart Schreiber of Harvard. Schreiber is an only partially human presence in the field, as a listing of his academic appointments will make clear: chairman, with an endowed professorship, of the Department of Chemistry at Harvard, investigator at the Howard Hughes… Read More
  • Drug Development

    The March of Folly Leader Board

    The first comment to the original March of Folly post below mirrors the e-mail I’ve received: the people’s choice for the technology most-likely-to-be-embarrassing is. . .(rustling of envelope): RNA interference. There’s a good case to be made for that, and it doesn’t contradict my oft-stated opinion that RNAi is going to be… Read More
  • Drug Assays

    How Drugs Die

    Everyone in the industry would like to do something about the failure rate of drugs in clinical trials. It would be far better to have not spent the time and money on these candidates, and the regret just increases as you move further down the process. A Phase I failure is painful; a Phase III… Read More
  • Cardiovascular Disease

    Sic Transit Gloria Mundi

    So Entremed is finally giving up on its celebrated peptide drug candidates, angiostatin and endostatin. I’m sorry to see what the company, and its employees have been through, but I’m even sorrier when I think about what cancer patients have been through during this story. Especially those of them who read that (in)famous New York… Read More
  • Drug Development

    New! Improved! Now With Stickier Lumps!

    An evergreen struggle inside a drug research company goes on between the chemists and the people who have to formulate their compounds. (By “formulate,” for those outside the business, I mean “put them into something that’ll allow them to be reproducibly given to animals.” This can be a pill, but in research it’s… Read More
  • Business and Markets

    What Sort of Number Did You Have in Mind?

    There’s a good article by Leandro Herrero in the October issue of Scrip magazine (no online content without a subscription.) He’s teeing off on the overuse of numerical measures in the drug industry (and industry in general:) “Your business education and experience tell you that if you can’t measure, you can’t manage.… Read More
  • Drug Development

    Structure-Inactivity Relationship Would Be More Like It

    Talking about pattern recognition leads a medicinal chemist to thoughts of SAR, structure-activity relationships. We spend a lot of time putting together tables of data – changes on one part of the molecule tabulated on one axis, changes in some other region on the other axis, and boxes filled in with the assay results. And… Read More
  • Drug Development

    You Don’t Hear “Eureka” That Often

    I actually wasn’t at work today – took the day off so that we could take the kids to the zoo. That probably means that something important happened; these things always seem to take place when I’m out of town. And the rest of the time something important happens in the lab, I generally don’t… Read More
  • Drug Development

    They All Get Real at Some Point

    In every drug development project, there are put-up-or-shut-up moments. Those are referred to by more traditional project planners as “milestones,” but everyone knows what they really are: the times when you walk across the fraying rope bridge, looking nervously at the depths below. A key moment is when your team has finally made some r… Read More
  • "Me Too" Drugs

    Our Buddies at the FDA

    Another question I’ve had posed to me is whether the FDA standards for drug approval are too tight (no one who writes to me seems to worry that they might be too loose, although you can find groups who’d argue just that.) Overall, I don’t think so. There are really two sets of standards, for… Read More
...535455